Why Siemens Healthineers Cut Its Sales Outlook Again

Siemens Healthineers has trimmed its revenue growth forecast for the fiscal year ending September for the second time, citing a sizable slump in its laboratory diagnostics business, especially in China. The company now expects comparable revenue to rise between 3.5% and 4.0%, down from the previous range of 4.5% to 5.0%.

The revision came as third-quarter comparable revenue grew just 2.8% to €5.82 billion, missing the 4.5% consensus among analysts. A 9.2% surge in the radiation therapy unit (Varian) and a modest 2.3% gain in imaging were outweighed by a 5.5% decline in diagnostics, with China posting a much sharper drop.

In a twist, the group raised its adjusted earnings per share outlook to between €2.35 and €2.45, up from €2.20–€2.30. The boost came entirely from a non-recurring refund of previously paid US trade tariffs, which helped push adjusted EBIT up 15.6% to €1.1 billion and the margin to 19.1%, beating analyst forecasts that had predicted declines.

CEO Bernd Montag described order momentum as “great” and stressed that the core synergistic businesses outside diagnostics proved robust in both sales and profit. However, the unscheduled tariff windfall masks the underlying operational performance, while the China-driven diagnostics weakness forced the second annual revenue target cut in a row.

Diagnostics Drag vs. One-Off Gain: The Mixed Picture Behind the Numbers

China’s Sharp Slowdown Hits Diagnostics Hard

The diagnostics unit’s 5.5% quarterly decline was amplified by an even steeper drop in China, a market that has been a growth engine for medical equipment. The contraction suggests not only post-pandemic normalization but also intensifying local competition and potentially delayed hospital spending amid government cost-containment efforts. With China remaining a strategic priority, the speed of recovery there will be a critical swing factor for the full-year top line.

Tariff Refund Conceals Operational Profit Trends

The earnings beat and raised EPS guidance are entirely attributable to a one-time US tariff refund, making the adjusted margin improvement artificially flattering. Excluding this windfall, underlying profitability would have been weaker, as the miss on revenue growth points to operating deleverage in the diagnostics division. Investors should be cautious: the refund is non-recurring, and next year’s comparisons will be tougher without such a tailwind.

Imaging and Varian: The Stabilizing Force

The 2.3% growth in imaging and the standout 9.2% jump in radiation therapy (Varian) demonstrate that the company’s non-diagnostics portfolio remains on solid footing. Varian’s strong order intake suggests a healthy pipeline, and imaging continues to benefit from hospital upgrade cycles. Together, these units provide a buffer, but they cannot fully compensate for a structural slowdown in diagnostics, which still contributes a significant share of group revenue.

What the Guidance Shake-Up Means for Investors and Peers

  • For Siemens Healthineers management: Rebuild diagnostics credibility by articulating a concrete China turnaround plan by the Q4 call. The second straight guidance downgrade erodes trust; a clear path to stabilization is now expected.
  • For investors: Strip out the €1.1 billion EBIT’s one-off boost to gauge true run-rate profitability. Consensus estimates for FY2026 EPS may need to come down once the tariff benefit lapses, unless diagnostics recovers quickly.
  • For competitors: The China diagnostics weakness may signal a wider market contraction. Rivals with heavy China exposure should stress-test their own forecasts; those with diversified portfolios could use the opening to gain share.
  • Supply chain and procurement teams: The tariff refund hints at past overpayment on US import duties. Re-evaluate duty management and potential further claims while trade policy remains fluid.

Risk & Opportunity Assessment

Commercial RiskHighThe diagnostic revenue miss, particularly in China, signals a faster-than-expected demand deterioration that forced a second annual guidance cut, threatening full-year top-line targets and potentially leading to further downgrades if the trend persists.
Competitive RiskMediumWhile no competitor is named, the sharp drop in China diagnostics suggests local rivals may be capturing share or pricing power is eroding; prolonged weakness could permanently impair Siemens Healthineers’ market position in a key region.
Regulatory RiskLowThe positive tariff refund shows trade policy can create windfalls, but no new regulatory hurdles are identified; the risk is minor and already priced into the one-off benefit.
Reputation RiskMediumA second consecutive guidance downgrade damages management’s forecasting credibility with analysts and investors, potentially leading to a valuation discount until consistent execution is restored.
Technology DisruptionLowNo evidence of product obsolescence; imaging and Varian showed healthy growth, suggesting the technology portfolio remains competitive.
Commercial OpportunityMediumStrong order momentum and robust performance in radiation therapy and imaging provide a foundation to offset diagnostics weakness; capturing further share in these growth segments while tackling the China headwind could lift sentiment if executed convincingly.